Dr. Oton is focused on clinical cancer research. Her major interest is in new drug development in lung cancer and thoracic malignancies. Dr. Oton will be the principal investigator on several therapeutic trials at Denver Health and the University of Colorado. She started her research career at the University of Pittsburgh with a focus in the differences in lung cancer survival between pre-menopausal and post-menopausal women.
Owonikoko T, Ragin C, Belani CP, Oton A, Gooding W, Taioli E, Ramalingam S Lung Cancer in Elderly Patients: An Analysis of the SEER Database, Accepted for publication in Journal of Clinical Oncology, August 2007
Feng R, Oton A, Mapara M, Anderson G, Belani C, Lentzsch S. The Histone Deacetylase Inhibitor, PXD101, potentiates bortezomib-induced and anti-multiple myeloma effect by Induction of Oxidative Stress and DNA Damage. Br J of Haematology November 2007, 139(3):385-397
Oton A, Hong W, Melhem M, George D, Foon K, Ghobrial IM. Clinical and Pathological Prognostic Markers for Survival in Adult Patients with Post-Transplant Lymphoproliferative Disorders, BCL2 as Poor Prognostic Marker. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I (supplement). June 2007, 25(18S): 8073
Oton A, Belani C, Siegfried J, Ramalingam S. Comparison of Survival for Lung Cancer between Premenopausal and Postmenopausal Women: An Analysis of the National Surveillance, Epidemiology and End Results (SEER) Database. 2006 ASCO Annual Meeting, JCO.